FDA approves first therapy for Alexander disease - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

  • By

  • Kathryn Wighton

  • September 4, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves first therapy for Alexander disease

At a Glance

CategoryDetail
ConditionAlexander disease
Key MechanismsMutations affecting the production of glial fibrillary acidic protein (GFAP) lead to accumulation and nervous system damage.
Target PopulationPediatric and adult patients with Alexander disease.
Care SettingMulticenter, randomized, controlled clinical study.

Key Highlights

  • Zilganersen (Zanvastro) is the first approved therapy for Alexander disease.
  • The drug is administered every 3 months via injection into the spinal canal.
  • Clinical trial showed improved walking speed in patients aged 5 years and older.
  • Motor assessment improvements were noted in patients aged 2 to 4 years.
  • Common adverse reactions include vomiting, back pain, and headache.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis is based on clinical presentation and genetic testing for GFAP mutations.

Management

  • Zilganersen is indicated for treatment in pediatric and adult patients.

Monitoring & Follow-up

  • Monitor for adverse reactions, including aseptic meningitis.

Risks

  • Potential risks include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.

Patient & Prescribing Data

Patients aged 2 years and older with Alexander disease.

Pharmacokinetic modeling suggests similar drug levels in patients younger than 2 years.

Clinical Best Practices

  • Administer zilganersen by a trained healthcare professional.
  • Conduct regular assessments of motor function in treated patients.

Related Resources & Content

Original Source(s)

FDA approves first therapy for Alexander disease

  • by Kathryn Wighton

  • September 4, 2026

Related Content

Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome

The first controlled phase 3 trial of a genetic therapy for Dravet syndrome is now underway – with Phoenix Children's as one of 28 sites nationwide.

  • by

  • August 13, 2026

  • 4 min
American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy

This American Epilepsy Society (AES) practice guideline provides updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to <36 months.

  • by

  • August 14, 2026

  • 2 min
FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.